MedCity News

OCTOBER 27, 2023

Technology is transforming how clinical trials are run. A panel during MedCity News’ INVEST Digital Health conference discussed the tech trends shaping the design and execution of drug studies.

Biopharma 317

Biopharma Patients Pharma 317

MedCity News

JULY 6, 2022

Emergn Principal Consultant Mario Moreira shared insights on how pharma companies can use the principles of Value, Flow and Quality to shorten drug development timelines and deliver better patient outcomes through improved ways of working.

Pharma 325

Pharma Consulting Patients Manufacturing 325

MedCity News

AUGUST 12, 2024

FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. The post Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency appeared first on MedCity News.

FDA 306

FDA Pharma Competition Pharmaceutical 306

MedCity News

JUNE 27, 2024

Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. The post Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD appeared first on MedCity News.

Pharma 290

Pharma FDA Medical Patients 290

MedCity News

MARCH 18, 2024

As GenAI and other technologies advance the speed of development and the precision of drugs, pharma commercial teams need to make sure they are harvesting the right data with the right AI tools in order to ultimately reach the right patients.

Pharma 305

Pharma Sales Marketing Patients 305

MedCity News

FEBRUARY 14, 2024

2024 presents an exciting yet challenging landscape for global pharma marketers.

Marketing 288

Marketing Pharma Pharmaceutical Patients 288

MedCity News

JANUARY 10, 2023

Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.

Pharma 296

Pharma Patients Biopharma 296

MedCity News

FEBRUARY 23, 2023

FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.

Competition 279

Competition FDA Patients Pharma 279

MedCity News

DECEMBER 28, 2022

It fits in amongst the goal of running nimble and patient-centered studies. But, without legislation, it’s doubtful that pharma companies will give up ownership of participant data out of sheer goodwill. Putting data into the hands of participants is an important step in changing the traditional clinical trial paradigm.

Patients 264

Patients Pharma Biopharma 264

MedCity News

JUNE 16, 2023

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.

Pharma 311

Pharma Food and Drug Administration Recruitment Patients 311

Fierce Pharma

OCTOBER 3, 2024

Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)

Patients 130

Patients Biopharma Management Pharma 130

MedCity News

APRIL 23, 2024

ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The post FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery appeared first on MedCity News. The novel immunotherapy works by sparking activity from three types of immune cells.

FDA 321

FDA Patients Biopharma Pharma 321

MedCity News

SEPTEMBER 4, 2024

Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players.

Patients 321

Patients Medical Pharmaceutical Biopharma 321

MedCity News

OCTOBER 29, 2023

A panel at the MedCity News INVEST conference in Dallas discussed how new tech platforms help speed up the process of recruiting patients and running clinical trials. AI technologies have a role in the life sciences that goes beyond drug discovery.

Recruitment 338

Recruitment Pharma Patients Biopharma 338

MedCity News

NOVEMBER 20, 2024

We cannot change the fact that some patients must take multiple drugs, but we can certainly change how we manage it with careful coordination and communication among healthcare providers, and personalized medicine practices such as pharmacogenomics.

Management 297

Management Medical Healthcare Provider Medicine 297

MedCity News

NOVEMBER 17, 2024

Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.

Patients 306

Patients Biopharma Pharma 306

MedCity News

DECEMBER 9, 2024

Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex.

FDA 290

FDA Leads Marketing Patients 290

MedCity News

MAY 11, 2023

Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.

FDA 312

FDA Patients Pharmaceutical Biopharma 312

MedCity News

SEPTEMBER 5, 2024

Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. The post Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative appeared first on MedCity News.

Patients 289

Patients FDA Marketing Biopharma 289

Fierce Pharma

JUNE 6, 2024

AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. lawmakers.

Biopharma 169

Biopharma Pharma Patients 169

MedCity News

JUNE 21, 2024

The post The Role of Medical Affairs in Bridging Clinical Trial Access for All Patients appeared first on MedCity News. Underrepresentation of racial and ethnic groups and other historically disenfranchised populations in clinical trials continues to be a major challenge. Medical Affairs can help identify solutions.

Medical 298

Medical Patients Biopharma Pharma 298

Fierce Pharma

FEBRUARY 27, 2024

Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support. A seismic shift has occurred in the healthcare landscape.

Biopharma 170

Biopharma Patients Healthcare Healthcare 170

MedCity News

OCTOBER 10, 2023

Merith Basey, executive director of Patients For Affordable Drugs, believes the Medicare price negotiation program is here to stay, no matter who is president and no matter how many Big Pharma players file lawsuits. among pretty much everyone who isn’t a pharma company, she said during a session at Engage at HLTH. Her reasoning?

Pharma 306

Pharma Patients Biopharma 306

MedCity News

NOVEMBER 28, 2022

Cincor Pharma drug baxdrostat failed its Phase 2 test, falling short of the goal of reducing blood pressure in patients with uncontrolled hypertension. But results in a subgroup of patients showed double-digit declines, which the company said could inform the design of a Phase 3 clinical trial.

Pharma 326

Pharma Patients Biopharma 326

MedCity News

AUGUST 30, 2022

the European Union and other countries amid ongoing efforts to encourage patients who want to share their data. In a recent interview, Jennifer Cubino, COO of BC Platforms, discussed regulatory differences between the U.S.,

Patients 279

Patients Biopharma Pharma 279

MedCity News

JANUARY 28, 2024

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.

Competition 325

Competition Medicine Pharma Patients 325

MedCity News

APRIL 8, 2024

The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products. The post Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs appeared first on MedCity News.

FDA 317

FDA Patients Marketing Biopharma 317

MedCity News

OCTOBER 24, 2022

The patient who died in the Phase 1 test of Alpine Immune Sciences drug, davoceticept, reportedly suffered the same cardiovascular complication as the first patient. The biotech company is stopping enrollment in two clinical tests of the drug and assessing all patients in the studies.

Patients 287

Patients Biopharma Pharma 287

MedCity News

AUGUST 5, 2022

Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein HER2. The decision makes the infused therapy the first targeted treatment for this new category of breast cancer patients.

FDA 299

FDA Patients Biopharma Pharma 299

MedCity News

FEBRUARY 20, 2024

The FDA clinical hold follows a patient death from liver failure that may be associated with zelnecirnon, an experimental Rapt Therapeutics drug. The biotech notes that no other patient has experienced liver problems and this safety signal has not been seen in any other tests of the molecule.

FDA 289

FDA Patients Safety Biopharma 289

MedCity News

AUGUST 7, 2022

Acadia Pharmaceuticals drug Nuplazid failed to win FDA approval for the treatment of psychosis in Alzheimer’s disease patients. The regulator said that the data submitted were not from an adequate and well-controlled study and the company must run another clinical trial.

FDA 299

FDA Pharma Pharmaceutical Patients 299

MedCity News

NOVEMBER 14, 2023

Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”

Leads 290

Leads Pharma Pharmaceutical Patients 290

MedCity News

MARCH 27, 2025

Soleno Therapeutics Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare disease, a leading cause of childhood obesity.

Leads 227

Leads FDA Patients Biopharma 227

MedCity News

JULY 10, 2024

The post Amylyx Aims to Help Patients With a Novel GLP-1 Drug, But Not the Way You Think appeared first on MedCity News. Amylyx plans to advance this GLP-1 antagonist into Phase 3 testing for post-bariatric hypoglycemia, a rare condition in which blood sugar levels drop precipitously.

Patients 293

Patients Pharmaceutical Marketing Biopharma 293

MedCity News

FEBRUARY 2, 2025

As the pharmaceutical landscape evolves, small-molecule CDMOs will be essential in balancing supply and demand, driving innovation, and improving patient outcomes. They must continue embracing innovation and strategic agility to survive and thrive in this complex environment.

Pharmaceutical 262

Pharmaceutical Patients Biopharma Pharma 262

Fierce Pharma

SEPTEMBER 27, 2024

Patients with rare or complex diseases often struggle to find specialists who meet their specific condition and individual needs. Patients with rare or complex diseases struggle to find specialists who fit their unique needs, delaying crucial care. Digital tools can help.

Biopharma 130

Biopharma Patients 130

MedCity News

NOVEMBER 20, 2022

While attention is focused on the former Lilly asset, also at stake is Acrivon’s technology platform that relies on proteomics rather than genomics for identifying patients appropriate for targeted therapies.

Patients 289

Patients Biopharma Pharma 289